Clinical trials: Central Line
Glabellar Frown Lines
A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001
The primary objective is to demonstrate the safety and efficacy of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in the treatment of moderate to severe glabellar lines associated with corrugator and/or procerus muscle…
- Trial name
- NCT02334423
- Testing
- Botulinum toxin, Type A, 0.9% sterile, unpreserved saline
- Where
- United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Alzheimer Disease, Dementia
Testing Tele-Savvy, an On-line Psychoeducation Program for Dementia Family Caregivers
The purpose of this study is to test the psychoeducational program "Tele-Savvy." Tele-Savvy is an internet based, group education program developed from an in person program called Savvy Caregiver.
- Trial name
- NCT03033875
- Testing
- Tele-Savvy, Healthy Living Education Program
- Where
- United States
- Volunteers
- 261 people, healthy volunteers welcome
- Sponsor
- Emory University
Glabellar Frown Lines
Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines
The purpose of this study is to demonstrate the safety of multiple doses of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in treatment of moderate to severe glabellar lines in adult subjects.
- Trial name
- EV-004 (NCT02184988)
- Testing
- Botulinum purified neurotoxin, Type A
- Where
- United States
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Frown Lines
Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006
The primary objective is to demonstrate the safety of multiple doses of DWP-450 purified Botulinum neurotoxin, Type A, in treatment of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in…
- Trial name
- EV-006 (NCT02428608)
- Testing
- DWP-450 (Botulinum purified neurotoxin, Type A)
- Where
- United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Lines, Wrinkles
Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines
This study is designed to evaluate the safety, efficacy, and subject and investigator satisfaction of 2 different injection volumes of Dysport in the glabellar lines. 1.
- Trial name
- NCT02718118
- Testing
- Dysport reconstituted at 1.5 mL (0.05 mL/injection), Dysport reconstituted at 2.5 mL (0.08 mL/injection)
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Nasolabial Folds, Marionette Lines
Emervel for the Correction of Lower Face Wrinkles & Folds
This study is designed to 1. evaluate the naturalness of facial expressions in motion (2D video images), by treating investigator assessment 2.
- Conditions
- Nasolabial Folds, Marionette Lines, Wrinkles
- Trial name
- NCT02718040
- Testing
- Emervel Classic and/or Deep Treatment Group
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Smoking, Smoking Cessation
Wisconsin Tobacco Quit Line Medicaid Incentive Evaluation
The study is designed to test the hypotheses that financial incentives can increase both participation in smoking cessation treatment and resulting cessation rates, when they are offered to BadgerCare Plus (Medicaid) smokers as…
- Conditions
- Smoking, Smoking Cessation, Nicotine Dependence
- Trial name
- NCT02713594
- Testing
- Counseling from WTQL, Financial incentive to participate
- Volunteers
- 1,900 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Chest Wrinkles
Evaluation of the Ulthera System for the Treatment of the Decolletage
This is prospective, multi-center clinical trial. Enrolled subjects will receive one Ulthera® treatment on the decolletage. Follow-up visits will occur at 90 and 180 days following treatment.
- Trial name
- NCT01713686
- Testing
- Ulthera System Treatment
- Where
- 4 sites in United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Ulthera, Inc
Chronic Graft-versus-host-disease
Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy
This is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of KD025 in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least 2 prior lines of systemic therapy
- Trial name
- NCT03640481
- Testing
- Belumosudil (KD025)
- Where
- 35 sites in United States
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Kadmon, a Sanofi Company
Glabellar Frown Lines
A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002
The primary objective is to demonstrate the safety and efficacy of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in the treatment of moderate to severe glabellar lines associated with corrugator and/or procerus muscle…
- Trial name
- EV-002 (NCT02334436)
- Testing
- Botulinum toxin, Type A, 0.9% sterile, unpreserved saline
- Where
- United States
- Volunteers
- 324 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.